Advertisement

Journal of General Internal Medicine

, Volume 20, Issue 12, pp 1151–1158 | Cite as

The efficacy and safety of exogenous melatonin for primary sleep disorders a meta-analysis

  • Nina Buscemi
  • Ben Vandermeer
  • Nicola Hooton
  • Rena Pandya
  • Lisa Tjosvold
  • Lisa Hartling
  • Glen Baker
  • Terry P. Klassen
  • Sunita Vohra
Clinical Review

Abstract

BACKGROUND: Exogenous melatonin has been increasingly used in the management of sleep disorders.

PURPOSE: To conduct a systematic review of the efficacy and safety of exogenous melatonin in the management of primary sleep disorders.

DATA SOURCES: A number of electronic databases were searched. We reviewed the bibliographies of included studies and relevant reviews and conducted hand-searching.

STUDY SELECTION: Randomized controlled trials (RCTs) were eligible for the efficacy review, and controlled trials were eligible for the safety review.

DATA EXTRACTION: One reviewer extracted data, while the other verified data extracted. The Random Effects Model was used to analyze data.

DATA SYNTHESIS: Melatonin decreased sleep onset latency (weighted mean difference [WMD]: −11.7 minutes; 95% confidence interval [CI]: −18.2, −5.2)); it was decreased to a greater extent in people with delayed sleep phase syndrome (WMD: −38.8 minutes; 95% CI: −50.3, −27.3; n=2) compared with people with insomnia (WMD: −7.2 minutes; 95% CI: −12.0, −2.4; n=12). The former result appears to be clinically important. There was no evidence of adverse effects of melatonin.

CONCLUSIONS: There is evidence to suggest that melatonin is not effective in treating most primary sleep disorders with short-term use (4 weeks or less); however, additional large-scale RCTs are needed before firm conclusions can be drawn. There is some evidence to suggest that melatonin is effective in treating delayed sleep phase syndrome with short-term use. There is evidence to suggest that melatonin is safe with short-term use (3 months or less).

Key Words

melatonin sleep primary review 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    National Institutes of Health. National Center on Sleep Disorder Research Plan. 2003.Google Scholar
  2. 2.
    Roller L. Treating sleep disorders. Aust J Pharm. 2002;83:443–7.Google Scholar
  3. 3.
    American Psychiatric Association. American Psychiatric Task Force on DSM-IV, Diagnostic and Statistical Manual of Mental Disorders: DSM IV. 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar
  4. 4.
    Grustein R. Insomnia diagnosis and management. Aust Fam Phys. 2002;31:995–1000.Google Scholar
  5. 5.
    American Academy of Sleep Medicine. The International Classification of Sleep Disorders, Revised. Diagnostic and Coding Manual. Rochester, Minn: American Academy of Sleep Medicine; 2001.Google Scholar
  6. 6.
    Regestein QR, Pavlova M. Treatment of delayed sleep phase syndrome. Gen Hosp Psychiatr. 1995;17:335–45.CrossRefGoogle Scholar
  7. 7.
    Wyatt JK. Delayed sleep phase syndrome: pathophysiology and treatment options. Sleep. 2004;27:1195–203.PubMedGoogle Scholar
  8. 8.
    Reite M, Ruddy J, Nagel K. Evaluation and Management of Sleep Disorders. 3rd ed. Washington, DC: American Psychiatric Publishing Inc; 2002.Google Scholar
  9. 9.
    Wagner DR. Circadian rhythm sleep disorders. Curr Treat Options Neurol. 1999;1:299–308.PubMedCrossRefGoogle Scholar
  10. 10.
    Czeisler CA, Kronauer RE, Allan JS, et al. Bright light induction of strong (type 0) resetting of the human circadian pacemaker. Science. 1989;244:1328–33.PubMedCrossRefGoogle Scholar
  11. 11.
    Reiter RJ. Melatonin: clinical relevance. Best Pract Res Clin Endocrinol Metab. 2003;17:273–85.PubMedCrossRefGoogle Scholar
  12. 12.
    Anton-Tay F, Diaz JL, Fernandez-Guardiola A. On the effect of melatonin upon human brain. Its possible therapeutic implications. Life Sci-Part 1-Physiol Pharmacol. 1971;10:841–50.CrossRefGoogle Scholar
  13. 13.
    Cramer H, Rudolph J, Consbruch U, Kendel K. On the effects of melatonin on sleep and behavior in man. Adv Biochem Psychopharmacol. 1974;11:187–91.PubMedGoogle Scholar
  14. 14.
    Arendt J, Borbely AA, Franey C, Wright J. The effects of chronic, small doses of melatonin given in the late afternoon on fatigue in man: a preliminary study. Neurosci Lett. 1984;45:317–21.PubMedCrossRefGoogle Scholar
  15. 15.
    Lieberman HR, Waldhauser F, Garfield G, Lynch HJ, Wurtman RJ. Effects of melatonin on human mood and performance. Brain Res. 1984;323:201–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials. 1996;17:1–12.PubMedCrossRefGoogle Scholar
  17. 17.
    Schulz KF, Chalmers I, Hayes RJ, Altman D. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. J Am Med Assoc. 1995;273:408–12.CrossRefGoogle Scholar
  18. 18.
    Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomized and non-randomized studies of health care interventions. J Epidemiol Commun Health. 1998;52:377–84.CrossRefGoogle Scholar
  19. 19.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  20. 20.
    Deeks JJ, Higgins JPT, Altman DG. Cochrane Statistical Methods Group. Analysing and presenting results: Section 8. In: Alderson P, Green S, Higgins JPT, eds. Cochrane Reviewer’s Handbook 4.2.2 [updated March 2004]; The Cochrane Library, Issue 1. Chichester, UK: John Wiley & Sons Ltd.; 2004.Google Scholar
  21. 21.
    Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.PubMedCrossRefGoogle Scholar
  22. 22.
    Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Eggar M, Smith GD, Altman DG, eds. Systematic Reviews in Health Care: Meta-analysis in context. 3rd ed. London: BMJ Publishing Group; 2001:285–312.Google Scholar
  23. 23.
    Garfinkel D, Laudon M, Nof D, Zisapel N. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet. 1995;346:541–4.PubMedCrossRefGoogle Scholar
  24. 24.
    Garfinkel D, Laudon M, Zisapel N. Improvement of sleep quality by controlled-release melatonin in benzodiazepine-treated elderly insomniacs. Arch Gerontol Geriatr. 1997;24:223–31.PubMedCrossRefGoogle Scholar
  25. 25.
    Smits MG, van Stel HF, van der Heijden K, Meijer AM, Coenen AM, Kerkhof GA. Melatonin improves health status and sleep in children with idiopathic chronic sleep-onset insomnia: a randomized placebo-controlled trial. J Am Acad Child Adolesc Psychiatr. 2003;42:1286–93.CrossRefGoogle Scholar
  26. 26.
    Zhdanova IV, Wurtman RJ, Regan MM, Taylor JA, Shi JP, Leclair OU. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab. 2001;86:4727–30.PubMedCrossRefGoogle Scholar
  27. 27.
    Andrade C, Srihari BS, Reddy KP, Chandramma L. Melatonin in medically ill patients with insomnia: a double-blind, placebo-controlled study. J Clin Psychiatr. 2001;62:41–5.CrossRefGoogle Scholar
  28. 28.
    Dawson D, Rogers NL, van den Heuvel CJ, Kennaway DJ, Lushington K. Effect of sustained nocturnal transbuccal melatonin administration on sleep and temperature in elderly insomniacs. J Biol Rhythm. 1998;13:532–8.CrossRefGoogle Scholar
  29. 29.
    Ellis CM, Lemmens G, Parkes JD. Melatonin and insomnia. J Sleep Res. 1996;5:61–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Baskett JJ, Broad JB, Wood PC, et al. Does melatonin improve sleep in older people?: a randomized crossover trial. Age Ageing. 2003;32:164–70.PubMedCrossRefGoogle Scholar
  31. 31.
    Smits MG, Nagtegaal EE, van der Heijden J, Coenen AM, Kerkhof GA. Melatonin for chronic sleep onset insomnia in children: a randomized placebo-controlled trial. Child Neurol. 2001;16:86–92.Google Scholar
  32. 32.
    Kayumov L, Brown G, Jindal R, Buttoo K, Shapiro CM. A randomized, double-blind, placebo-controlled crossover study of the effect of exogenous melatonin on delayed sleep phase syndrome. Psychosom Med. 2001;63:40–8.PubMedGoogle Scholar
  33. 33.
    Dahlitz M, Alvarez B, Vignau J, English J, Arendt J, Parkes JD. Delayed sleep phase syndrome response to melatonin. Lancet. 1991;337:1121–4.PubMedCrossRefGoogle Scholar
  34. 34.
    Montes LG, Ontiveros Uribe MP, Cortes Sotres J, Heinze Martin G. Treatment of primary insomnia with melatonin: a double-blind, placebo-controlled, crossover study. J Psychiatr Neurosci. 2003;28:191–6.Google Scholar
  35. 35.
    Buscemi N, Vandermeer B, Pandya R, et al. Melatonin for treatment of sleep disorders. Evid Rep Technol Assess (Summ). 2004;108:1–7.Google Scholar
  36. 36.
    Moher D, Sampson M, Campbell K, et al. Assessing the quality of reports of randomized trials in paediatric complementary and alternative medicine. BMC Paediatr. 2002;2:2 (available at: http://www.biomedcentral.com/1471-2431/2/2).CrossRefGoogle Scholar
  37. 37.
    Nahin RL, Straus SE. Research into complementary and alternative medicine problems and potential. BMJ. 2001;322:161–4.PubMedCrossRefGoogle Scholar
  38. 38.
    Cho MK, Bero LA. The quality of drug studies published in symposium proceedings. Ann Intern Med. 1996;124:485–9.PubMedGoogle Scholar
  39. 39.
    Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326:1167–70.PubMedCrossRefGoogle Scholar
  40. 40.
    Lewy AJ, Ahmed S, Jackson JM, Sack RL. Melatonin shifts human circadian rhythms according to a phase response curve. Chronobiol Int. 1992;9:380–92.PubMedGoogle Scholar
  41. 41.
    Ioannidis JPA, Evans SJW, Gotzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141:781–8.PubMedGoogle Scholar
  42. 42.
    Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001;285:437–43.PubMedCrossRefGoogle Scholar
  43. 43.
    Loke YK, Derry S. Reporting of adverse drug reactions in randomized controlled trials—a systematic survey. BMC. Clin Pharmacol. 2001;1:3.PubMedCrossRefGoogle Scholar
  44. 44.
    Barnes J, Mills S, Abbot N, Willoughby M, Ernst E. Different standards for reporting ADRs to herbal remedies and conventional OTC medications: face-to-face interviews with 515 users of herbal remedies. Br Clin Pharmacol. 1998;45:496–500.CrossRefGoogle Scholar
  45. 45.
    Moher D, Pham B, Lawson M, Klassen TP. The inclusion of reports of randomized trials published in languages other than English in systematic reviews. Health Technol Assess. 2003;7:1–90.PubMedGoogle Scholar

Copyright information

© Society of General Internal Medicine 2005

Authors and Affiliations

  • Nina Buscemi
    • 1
  • Ben Vandermeer
    • 1
  • Nicola Hooton
    • 1
  • Rena Pandya
    • 1
  • Lisa Tjosvold
    • 1
  • Lisa Hartling
    • 1
  • Glen Baker
    • 2
  • Terry P. Klassen
    • 1
  • Sunita Vohra
    • 3
  1. 1.University of Alberta Capital Health Evidence-based Practice Centre, Department of PediatricsUniversity of AlbertaEdmontonCanada
  2. 2.Department of PsychiatryUniversity of AlbertaEdmontonCanada
  3. 3.Complementary and Alternative Research and Education Program, Department of PediatricsUniversity of AlbertaEdmontonCanada

Personalised recommendations